Table 1.
MTX | O’Dell | ADA combination therapy | Associated HAQ change (normal dist) | HAQ change STDDEV | |
---|---|---|---|---|---|
ACR20 response (%) | 31 | 28 | 58 | −0.44266 | 0.01831 |
ACR50 response (%) | 11 | 15 | 36 | −0.66795 | 0.02610 |
ACR70 response (%) | 4 | 7 | 19 | −0.92257 | 0.03201 |
Duration shape parameter | 0.51 | 0.49 | 0.73 | ||
Duration scale parameter | 15.73 | 7.31 | 5.96 | ||
Direct treatment costs (Q1) | 74.82 € | 220.34 € | 5,943.26 € | ||
Direct treatment costs (Qn) | 77.99 € | 223.51 € | 5,757.71 € |